Durvalumab Pre, Post Surgery in NSCLC: Practice Changing? :

The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer.

Related Keywords

Connecticut , United States , Texas , Houston , Orlando , Florida , New Haven , American , America , Roys Herbst , Johnv Heymach , , University Of Texas Md Anderson Cancer Center , American Association For Cancer Research , Yale Cancer Center , Astrazeneca , American Association , Cancer Research , Annual Meeting , Cancer Center , Medscape Medical , South America , Lung Cancer , Ung Carcinoma , Ancer Lung , Neoadjuvant , Biologic Therapy , Non Small Cell Lung Cancer , Nsclc , Small Cell Lung Cancer , Chemotherapy , Cancer , Alignant Neoplasia , Arcinoma , Surgery , Immunotherapy , Lung ,